Stock 688176 JIANGSU YAHONG MEDITECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Jiangsu Yahong Meditech Co., Ltd. Stock

Equities

688176

CNE100005XW0

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
6.71 CNY -1.76% Intraday chart for Jiangsu Yahong Meditech Co., Ltd. +1.36% -37.76%
Apr. 29 Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 105M 14.54M Sales 2025 * 302M 41.76M Capitalization 3.84B 532M
Net income 2024 * -359M -49.73M Net income 2025 * -334M -46.26M EV / Sales 2024 * 36.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
-10.7 x
P/E ratio 2025 *
-11.4 x
Employees 394
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.69%
More Fundamentals * Assessed data

Chart Jiangsu Yahong Meditech Co., Ltd.

Dynamic Chart

Latest news about Jiangsu Yahong Meditech Co., Ltd.

Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. CI
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN CI
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan MT
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan. CI
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU CI
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization CI
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit CI
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024. CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China CI
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting CI
More news

Quotes and Performance

1 day-1.76%
1 week+1.36%
Current month+1.36%
1 month+1.51%
3 months+22.00%
6 months-41.35%
Current year-37.76%
More quotes

Highs and lows

1 week
6.67
Extreme 6.67
6.87
1 month
5.40
Extreme 5.4
6.87
Current year
4.61
Extreme 4.61
10.90
1 year
4.61
Extreme 4.61
16.18
3 years
4.61
Extreme 4.61
20.00
5 years
4.61
Extreme 4.61
20.00
10 years
4.61
Extreme 4.61
20.00
More quotes

Managers and Directors - Jiangsu Yahong Meditech Co., Ltd.

Managers TitleAgeSince
Ke Pan CEO
 Chief Executive Officer 56 10-03-15
Ming Yuan Yang DFI
 Director of Finance/CFO 41 20-12-10
Cheng Feng Zhuang COO
 Chief Operating Officer 61 19-07-10
Members of the board TitleAgeSince
Bing Hui Zhang BRD
 Director/Board Member 61 20-12-10
Xin Ming Jiang BRD
 Director/Board Member 54 21-01-24
Ke Pan CEO
 Chief Executive Officer 56 10-03-15
More insiders

Quotes

Date Price Change Volume
24-05-08 6.71 -1.76% 5,408,083
24-05-07 6.83 +1.79% 5,605,567
24-05-06 6.71 +1.36% 7,474,297
24-04-30 6.62 -0.75% 7,576,371

End-of-day quote Shanghai S.E., May 07, 2024

More quotes

Company Profile

Jiangsu Yahong Meditech Co Ltd is a China-based company mainly engaged in drug research and development (R&D). The Company focuses on innovative drugs in the field of urogenital tumors and other major diseases. The product pipelines being developed by the Company include APL-1202, APL-1501, APL-1706, APL-1702, ASN-1764, ASN-1780, APL-1901, APL-1401, ASN-1733 and others. The Company is still in the R&D stage.
Sector
Biotechnology & Medical Research
Calendar
2024-08-21 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Yahong Meditech Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.71 CNY
Average target price
12.28 CNY
Spread / Average Target
+83.08%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
JIANGSU YAHONG MEDITECH CO., LTD. Stock Jiangsu Yahong Meditech Co., Ltd.
-37.76% 529M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.49% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.60% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-11.26% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-7.29% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.31% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.19% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688176 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW